(Reuters) – Pfizer and French counterpart Valneva said on Thursday that a phase 2 study of its Lyme disease vaccine candidate VLA15 had shown a “strong immune response” in children and adolescents a month after injection of a booster dose.
“These Phase 2 results from the use of a booster dose underscore the potential of the vaccine to generate immunity against Lyme disease in the pediatric and adolescent population,” the two pharmaceutical companies said in a statement.
The candidate vaccine was “well tolerated in all study age groups” after the booster dose.
Pfizer said it wants to submit regulatory applications for VLA15, which Valneva touts as “the most advanced vaccine candidate” against Lyme disease, to the European Medicines Agency (EMA) and Food and Drug Administration (FDA). United States by 2026 if the phase 3 clinical trial, launched last year, shows positive results.
The New York-based pharmaceutical giant has previously said it aims to file for regulatory approvals by 2025.
(Victor Goury-Laffont, Stéphanie Hamel)
Copyright © 2023 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
